Assessing no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis receiving fingolimod: results from a longitudinal, multicenter, real-world study

被引：0

作者：

Weinstock-Guttman, Bianca ^{[1
]}

Medin, Jennie ^{[2
]}

Khan, Nasreen ^{[3
]}

Korn, Jonathan ^{[3
]}

Price, Jenny ^{[3
]}

Silva, Diego ^{[2
]}

Lathi, Ellen ^{[4
]}

Silversteen, Jason ^{[5
]}

Edwards, Keith ^{[6
]}

Zivadinov, Robert ^{[7
,8
]}

机构：

[1] Univ Buffalo State Univ New York, Jacobs Multiple Sclerosis Ctr, Dept Neurol, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA

[2] Novartis Pharma AG, Basel, Switzerland

[3] QuintilesIMS, Basel, Switzerland

[4] Elliot Lewis Multiple Sclerosis Ctr, Boston, MA USA

[5] Christiana Care Multiple Sclerosis Ctr, Newark, DE USA

[6] MS Ctr Northeastern New York, Latham, NY USA

[7] Buffalo Neuroimaging Anal Ctr, Dept Neurol, Buffalo, NY USA

[8] Univ Buffalo State Univ New York, MR Imaging Clin Translat Res Ctr, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P4.388

引用

页数：3